The p53 tumor suppressor controls cell growth and survival through transcriptional regulation of gene expression. Previously, we found that the human telomerase reverse transcriptase (hTERT) gene is downregulated by p53. To investigate if hTERT downregulation has a role in p53-dependent apoptosis, we tested if constitutive expression of telomerase could inhibit p53-induced apoptosis. Here we show that constitutive hTERT expression results in increased survival following activation of exogenous temperature-sensitive p53 in BL41 Burkitt lymphoma cells. Similarly, constitutive hTERT expression inhibited wild-type p53-dependent apoptosis in response to mitomycin C or 5-fluorouracil in HCT116 colon carcinoma cells carrying endogenous p53. A telomerase-inactive hTERT mutant was equally efficient in antagonizing p53-induced apoptosis. These findings support the notion that hTERT has antiapoptotic activity and demonstrate that p53-mediated downregulation of hTERT is critical for efficient p53-dependent apoptosis.
Introduction
The p53 tumor suppressor has a key role in the control of normal cell growth, genomic stability and cell survival, thus protecting against tumor development (Vousden and Lu, 2002) . Cellular stress, such as DNA damage, oncogene activation and hypoxia, triggers p53 protein accumulation and p53-mediated transcriptional transactivation of target genes, including p21, Bax and PUMA, which regulate cell cycle arrest or apoptosis (Vogelstein et al., 2000; Vousden and Lu, 2002) . p53-deficient mice are highly prone to various spontaneous tumors (Donehower et al., 1992; Attardi and Jacks, 1999) . Around 50% of all human tumors carry point mutant p53 (www.iarc.fr/p53). The p53 tumor suppressor pathway is inactivated in many and perhaps all wildtype p53-carrying tumors as well, for example, by overexpression of the p53 antagonist MDM2 or loss of the p14ARF protein that induces p53 in response to oncogene activation (Lowe and Sherr, 2003) . p53 not only transactivates target genes but also transrepresses specific genes, including the antiapoptotic Bcl-2 gene, the insulin-like growth factor receptor gene (IGF1R) and the microtubuli-associated protein 4 (MAP4) gene (Miyashita et al., 1994; Murphy et al., 1996; Werner et al., 1996) . Constitutive expression of these genes was shown to inhibit p53-induced apoptosis Murphy et al., 1996; Prisco et al., 1997) , indicating that their downregulation is important for the p53-dependent apoptotic response.
Human telomerase reverse transcriptase (hTERT) stabilizes chromosomal ends by extending the telomeric repeat sequences and plays a critical role in cellular survival, development and functions of multiple tissues and organs (Greider and Blackburn, 1996; Lee et al., 1998) . hTERT activity is repressed in normal somatic tissues, but both hTERT expression and activity are elevated in most human tumors (Kim et al., 1994) . Expression of hTERT in telomerase-negative normal human cells is associated with extension of cellular lifespan (Bodnar et al., 1998; Counter et al., 1998) , whereas inhibition of hTERT limits growth of cancer cells (Hahn et al., 1999) . We have previously shown that the hTERT gene is downregulated upon activation of wild-type p53, possibly through inhibition of Sp1 binding to the hTERT promoter (Xu et al., 2000) . This is consistent with several reports showing that hTERT activity is inhibited when p53 is overexpressed in human cancer cells (Kusumoto et al., 1999; Kanaya et al., 2000) . Additionally, inactivation of p53 in telomerasenegative human mammary epithelial cells (HMEC) led to rapid reactivation of telomerase (Stampfer et al., 2003) .
Several studies have indicated that hTERT has an antiapoptotic activity in addition to its role in telomere length maintenance. Ectopic expression of hTERT results in resistance to serum starvation-induced apoptosis and protection from stress-induced apoptosis (Holt et al., 1999; Gorbunova et al., 2002) . Moreover, hTERT appears to have a role in tumorigenesis independently of its ability to maintain telomeres (Stewart et al., 2002) . These observations and our finding that telomerase is downregulated by activation of wild-type p53 led us to hypothesize that transrepression of hTERT is required for efficient p53-induced apoptosis. To test this hypothesis, we examined whether constitutive expression of hTERT could inhibit wild-type p53-induced apoptosis using two different cell systems. We show here that constitutive expression of hTERT counteracts apoptosis induced by either exogenous temperature-sensitive p53 or endogenous wild-type p53, and that this effect is independent of telomerase activity.
Results

hTERT is downregulated by p53 in HCT116 p53
þ / þ cells
To confirm that hTERT is downregulated by endogenous wild-type p53 in response to DNA damage, we treated isogenic HCT116 colon carcinoma cells carrying intact p53 or lacking p53 (Bunz et al., 1998) with 10 mg/ml of mitomycin C (MMC) and analysed hTERT expression at different time points. hTERT protein was significantly reduced at 24 h after MMC treatment in the p53 þ / þ HCT116 cells but not in the isogenic p53 À/À cells ( Figure 1a ). RT-PCR confirmed p53-dependent downregulation of hTERT after 16 h of MMC treatment (Figure 1b) . Immunostaining also showed reduced hTERT protein levels upon p53 activation in the p53 þ / þ cells. We noted an increased number of cells with nucleolar hTERT staining after p53 activation (Figure 1c) . hTERT protein levels were also reduced in BL41 Burkitt lymphoma cells carrying temperaturesensitive p53 (BL41-ts p53) after activation of wild-type p53 by temperature shift to 321C, whereas the p53 target p21 was induced (Figure 1d ).
Constitutive expression of hTERT inhibits p53-induced apoptosis in BL41-ts p53 cells
If downregulation of hTERT is critical for p53-dependent apoptosis, constitutive ectopic expression of hTERT should inhibit this response. We transfected BL41-ts p53 (Ramqvist et al., 1993) cells with hTERTpBabe or empty vector. We also transfected the cells with a Bcl-2-pBabe construct as positive control for apoptosis protection. Clones of transfected cells were identified by PCR using construct-specific primers (Figure 2a ). Three clones expressing exogenous hTERT hTERT antagonizes p53-induced apoptosis independently of telomerase activity R Rahman et al were designated hT21, hT26 and hT27. We confirmed constitutive expression of hTERT by Western blotting. hTERT protein levels in the hTERT clones did not decrease upon activation of wild-type p53 by temperature shift to 321C for 24 h, whereas hTERT expression was clearly reduced in the untransfected control cells (Figure 2b ). Activation of wild-type p53 was confirmed by detection of the p53 targets p21 and MDM2 in cells incubated at 321C (Figure 2b and data not shown). We also confirmed expression of Bcl-2 in clone B4 and upregulation of MDM2 upon temperature shift to 321C (Figure 2c ).
To determine if constitutive hTERT expression had any effect on wild-type p53-induced cell death, the cells were incubated at 321C for 24 h and then analysed by Trypan blue staining. Around 50% of the untransfected parental BL41-ts p53 cells and vector-transfected control cells were alive at this time point. In contrast, 75-80% of the hTERT-transfected cells and 90% of the Bcl-2-transfected cells were alive (Figure 3a) . FACS analysis confirmed this result, showing a marked decrease in apoptosis among hTERT and Bcl-2 transfectants as compared to the control cells (Figure 3b ).
TUNEL staining of the parental and vector-transfected BL41-ts p53 cells grown at 321C revealed a high fraction of apoptotic cells. Only a few TUNEL-positive cells were detected among the hTERT clones and almost none in the Bcl-2-transfected control cells (Figure 3c ). Virtually all cells grown at 371C were TUNEL negative (data not shown).
To exclude the trivial possibility that the resistance to apoptosis in the hTERT-transfected cells was due to loss of ts p53 expression, we performed p53 immunostaining. The BL41-ts p53 cells and all Bcl-2 and hTERT clones derived from these cells showed strong p53 immunostaining, whereas the parental BL41 cells only showed a weak p53 staining due to low level of expression of endogenous Gln-248 mutant p53 ( Figure 3d ).
hTERT inhibits endogenous wild-type p53-induced apoptosis independently of its role in telomere length maintenance
The effect of constitutive hTERT expression on endogenous wild-type p53-induced apoptosis was examined using the isogenic HCT116 colon carcinoma cells carrying wild-type p53 or lacking p53. Both cells were transfected with hTERT-pBabe and also DNhTERT-pBabe that encodes a dominant-negative catalytically inactive mutant of hTERT. pBabe vector was used as negative control and Bcl-2-pBabe served as positive control for apoptosis protection. Pools of transfected cells were grown under selection, and presence of the transfected plasmid was verified by PCR and Western blotting (data not shown). Activation of wild-type p53 by treatment with the DNA-damaging agent MMC caused a marked downregulation of hTERT in the vector-transfected control cells, but not in the hTERT or DN-hTERT-transfected cells (Figure 4a ). Significant levels of Bcl-2 were expressed in the Bcl-2-transfected cells (Figure 4b ). RT-PCR confirmed p53-dependent downregulation of hTERT mRNA in vector-transfected cells, but not in hTERT or DN-hTERT-transfected cells (Figure 4c ). We assessed telomerase activity in HCT116 p53
þ / þ cells transfected with wt hTERT or DN-hTERT using the TRAP assay. As expected, the wt hTERT-transfected cells, but not the DN-hTERT-transfected cells, showed elevated telomerase activity as compared to vector-transfected cells (Supplementary Figure 6) .
Apoptosis was assessed following activation of endogenous p53 by treatment with MMC or 5-fluorouracil (5-FU). Flow-cytometric assay of cells (Figure 5a ). Only 23% of the hTERT-transfected cells and 21% of the DN-hTERT-transfected cells were apoptotic at 24 h, whereas 42% of the vector-transfected cells were dead or dying at this time point. The fraction of apoptotic Bcl-2-transfected cells at 24 h after MMC treatment was only marginally increased. Constitutive hTERT, DN-hTERT or Bcl-2 expression also protected against apoptosis induced by 5-FU, although somewhat less efficiently (Figure 5a ). Treatment of HCT116 cells lacking p53 with MMC or 5-FU induced a weaker apoptotic response at 24 h, which was not inhibited by constitutive hTERT or DN-hTERT expression (Figure 5b ). However, Bcl-2 provided some protection against 5-FUinduced apoptosis in these cells. Constitutive expression of hTERT or DN-hTERT also inhibited p53-induced apoptosis at 48 h of exposure to MMC or 5-FU, but less efficiently. Around 60% of the hTERT-or DN-hTERTtransfected cells were apoptotic at this time point, compared to slightly more than 75% of the vectortransfected control cells. Only 25% of the Bcl-2-transfected cells were dead at 48 h of MMC treatment. Similar results were obtained after 5-FU treatment (data not shown). TUNEL staining also showed decrease number of apoptotic cells in the p53-positive HCT116 cells transfected with hTERT, DN-hTERT or Bcl-2 (Figure 5c ).
hTERT promotes cell survival despite p53-induced apoptosis Next, we investigated the ability of hTERT and DNhTERT to overcome p53-induced apoptosis and promote cell growth in a colony formation assay. HCT116 p53 þ / þ cells transfected with the different constructs were exposed to 5-FU for 20 h, washed and allowed to hTERT antagonizes p53-induced apoptosis independently of telomerase activity R Rahman et al grow in fresh media for 2-3 weeks to establish colonies. Strikingly, cells transfected with hTERT, DN-hTERT or Bcl-2 formed significantly more colonies than vectortransfected cells (Figure 5d and e). The Bcl-2-transfected cells formed the largest number of colonies. In contrast, we did not observe any significant differences in the number of colonies formed by 5-FU-treated HCT116 p53 À/À cells transfected with the same constructs (not shown).
Discussion
Previous studies have shown that critical telomere shortening in dividing human diploid fibroblasts (HDFs) can trigger p53-dependent induction of p21 and cell cycle arrest (Vaziri and Benchimol, 1996) . Moreover, the p53 pathway is activated in mouse embryo fibroblasts from late-generation mice lacking telomerase activity (Chin et al., 1999) . These findings indicate that telomere shortening can trigger a p53-dependent DNA damage response that will block cell cycle progression or trigger apoptosis to prevent further growth of cells that fail to maintain proper telomere length. Our previous finding that p53 can transrepress hTERT transcription provided a novel link between p53 and telomerase activity (Xu et al., 2000) . Here we asked whether p53-mediated transrepression of hTERT transcription has a role in p53-induced apoptosis. Our results demonstrate that constitutive hTERT expression antagonizes p53-induced apoptosis. Importantly, we found that constitutively expressed hTERT inhibited p53-induced apoptosis in both Burkitt lymphoma cells carrying exogenous temperature-sensitive p53 that is activated at 321C and in colon carcinoma cells carrying endogenous wild-type p53 activated by DNA-damaging agents. Although constitutive hTERT expression conferred a significant protection from p53-induced apoptosis, it was less efficient than that provided by constitutive Bcl-2 expression.
We found that telomerase activity is not required for hTERT-mediated inhibition of p53-induced apoptosis, since a catalytically inactive dominant-negative mutant of hTERT (DN-hTERT) was as efficient as wild-type hTERT in antagonizing p53-induced apoptosis. This is consistent with other studies showing that hTERT can promote cell survival independently of its enzymatic activity (Cao et al., 2002) , and that telomere-independent activities of hTERT can contribute to tumor development (Stewart et al., 2002) . However, Smith et al. (2003) found that dominant-negative catalytically inactive hTERT failed to enhance cell growth under conditions when wild-type hTERT was able to do so. Therefore, it is possible that hTERT has several growthand survival-promoting functions, some of which require telomerase activity and some of which act telomere-independently (Gorbunova and Seluanov, 2003) .
What are the molecular mechanisms behind the ability of hTERT to antagonize p53-induced apoptosis? Constitutive expression of hTERT in HMECs resulted in activation of certain growth-promoting genes, including the epidermal growth factor receptor (EGFR), and repression of some proapoptotic genes, for example, TNF-related apoptosis-inducing ligand (TRAIL) . A similar mechanism could account for the effect of constitutively expressed hTERT on p53-induced apoptosis. This possibility could be addressed by microarray analysis. In addition, the identification and further studies of hTERT-interacting proteins may reveal potential antiapoptotic pathways involving hTERT.
We conclude from these findings that downregulation of endogenous hTERT by p53 has an important role for p53-induced apoptosis. p53-mediated downregulation of hTERT may be required for p53-dependent apoptosis in normal cells that express hTERT, for instance, Figure 5d . Standard deviation is indicated by the error bars hTERT antagonizes p53-induced apoptosis independently of telomerase activity R Rahman et al hematopoietic stem cells and germinal center B cells (Broccoli et al., 1995; Norrback et al., 2001) . The ability of p53 to downregulate hTERT may also be critical for the p53-dependent elimination of tumor cells that already express elevated levels of hTERT. Finally, p53 inactivation by various mechanisms in tumors may facilitate activation of hTERT and thus contribute to the limitless replicative potential of tumor cells.
Materials and methods
Cell lines and cell culture
BL41 cells carrying temperature-sensitive p53 and HCT116 p53 þ / þ and p53 À/À colon carcinoma cells were grown in IMDM supplemented with 10% fetal bovine serum, glutamin and gentamycin in 5% CO 2 at 371C. BL41-ts p53 cells were incubated at 321C for activation of wild-type p53. HCT116 cells were grown with or without 10 mg/ml mitomycin C (Sigma, St Louis, MI, USA) or 380 mM 5-FU (Sigma, St Louis, MI, USA) to induce endogenous p53 and harvested at indicated time points.
Plasmids and PCR
The pBABE-puro-hTERT and pBABE-puro-DN-hTERT plasmids were provided by Robert A Weinberg (MIT, Cambridge, MA, USA). The Bcl-2-pBABE plasmid was constructed by subcloning Bcl-2 cDNA from pSSV-Bcl-2, provided by Stanley Korsmeyer (Dana-Farber Cancer Institute, MA, USA) into the pBABE vector. PCR amplification and DNA sequencing were carried out using the following primers: pBabe-F (5 0 -GCCTCAATCCTCCCTTTATC-3 0 ), pBabe-R (5 0 -GCCGAGCCGCTGGTAGAAGG-3 0 ), hTERT-R (5 0 -AGGAGTAGAGGA AGTGCTTGGTGT-3 0 ) and Bcl-2-R (5 0 -GAATTCTCACTTGTGGCCCAG-3 0 ). RT-PCR was performed using the following primers: hTERT-RT-F (5 0 -CGGAAGAGTGTCTGGAGCAA-3 0 ) and hTERT-RT-R (5 0 -GGATGAAGCGGAGTCTGGA-3 0 ). PCR was performed using iCyclert (Bio-Rad, Hercules, CA, USA) and DNA sequencing using the ABI Prism Big Dye Termonator Cycle Sequencing Ready Reaction Kit (PE Applied Biosystems, MA, USA) and analysed on an ABI Prism 310 Genetic Analyser (Perkin-Elmer, MA, USA).
Transfections BL41-ts p53 cells were electroporated using Gene Pulser (BioRad, Hercules, CA, USA) set at 250 V and 960 mF. Cells were cloned and selected in 1 mg/ml puromycin (Sigma, St Louis, MI, USA). Genomic DNA was extracted from individual cell clones (Qiamp DNA blood mini kit, Hilden, Germany) and PCR amplification was carried out to confirm integration of the DNA construct in genomic DNA. HCT116 cells were transfected using 250 mM CaCl 2 , 2 Â HEBS buffer (pH 7.05) and 3 mg linearized DNA. Cells were grown under selection for 2-3 weeks before colonies were picked for expansion.
TRAP assay
Telomerase activity was measured with the TRAPeze telomerase detection kit (Chemicon, CA, USA). Cells were lysed with 1 Â CHAPS lysis buffer and the TS primers were labelled with g-32 P-ATP. PCR products were separated by electrophoresis on a 12.5% nondenaturing polyacrylamide gel and visualized by autoradiography.
Cellular assays
BL41-ts p53 cells grown at 37 and 321C were stained with 1 : 1 Trypan blue (Sigma, St Louis, MI, USA) to assess cell growth and viability. To measure DNA content, BL41-ts p53 cells grown as above and HCT116 cells treated with 4 mg/ml MMC or 380 mM 5-FU were fixed in 1 ml cold 70% ethanol for 16-24 h and stained with 10 mg/ml PI (Sigma, St Louis, MI, USA) and 25 mg/ml RNase and analysed by flow cytometry (BectonDickinson, Franklin Lakes, NJ, USA). The fraction of apoptotic cells was assessed from the number of cells with a sub-G1 DNA content. The mean value of sub-G1 cells from at least three individual experiments was calculated for estimation of apoptotic cells. TUNEL staining was performed on fixed cells on slides according to the manufacturer's protocol (Roche, Mannheim, Germany). Briefly, cells were fixed in 4% paraformaldhyde for 1 h, washed in PBS and permeabilized for 2 min on ice with 0.1% Triton X-100 and 0.1% sodium citrate in PBS. Cells were washed in PBS and incubated with 50 ml TUNEL reaction mix in a humidified chamber for 30 min at 371C. Slides were washed and analysed using an Axioplan II (3D) microscope equipped with an AxioCam CCD camera (Carl Zeiss, Oberkochen, Germany). For survival assays, HCT116 cells were treated with 4 mg/ml MMC or 385 mM 5-FU for 20 h, washed twice with PBS and media, and allowed to grow in fresh media for 2-3 weeks. Colonies were fixed with methanol and stained with Giemsa staining solution (Sigma, St Louis, MI, USA).
Western blot analysis
Protein extracts were prepared by lysis in 100 mM Tris at pH 8, 150 mM NaCl, 1% NP-40, 1 : 100 PMSF and 1 : 100 protease inhibitor cocktail (Sigma, St Louis, MI, USA). Protein concentrations were measured using the Bio-Rad Protein Assay based on the Bradford method. Total protein (50 or 100 mg) from treated and control cells was mixed with 4 Â loading buffer (100 mM Tris (pH 6.8), 200 mM dithiothreitol, 4% SDS, 0.2% bromophenol blue and 20% glycerol) and resolved by SDS-polyacrylamide gel electrophoresis (PAGE). After gel electrophoresis, the protein was transferred to PVDF membrane (Bio-Rad, Hercules, CA, USA). The following antibodies were used: mouse monoclonal anti-hTERT (NCL-hTERT, Novocastra, Newcastle, UK), (Supplementary Figure 7) mouse monoclonal anti-p53 (DO-1, Eurogenetics, Tessenderlo, Belgium), mouse monoclonal anti-p21 (Pharmigen, San Diego, CA, USA), mouse monoclonal anti-MDM2 (SMP14, Neomarkers, Fremont, CA, USA) or rabbit polyclonal anti-MDM2 (N-20, Santa Cruz, CA, USA), and mouse monoclonal anti-b-actin (Ac-15, Sigma, St Louis, MI, USA). Appropriate horseradish peroxidase-linked secondary antibodies (Amersham Biosciences, Buckinghamshire, UK) were visualized by enhanced chemiluminescence (Pierce, Rockford, IL, USA). b-Actin was used as loading control.
Immunofluorescence microscopy BL41-ts p53 cells grown at 371C, seeded into 4 cm 2 wells and collected by cytospin and HCT116 cells seeded on 12-mm coverslips were fixed in 4% paraformaldehyde before permeabilization in 0.2% NP-40 (Sigma, St Louis, MI, USA). Immunostaining was carried out using mouse monoclonal p53 antibody (ab421, Oncogene research products, s.d.) for staining of p53 in BL41-ts p53 cells and mouse monoclonal anti-hTERT (NCL-hTERT, Novocastra, Newcastle, UK) and rabbit polyclonal anti-p53 (FL-393, Santa Cruz, CA, USA) antibodies, followed by appropriate FITC or Texas redconjugated secondary antibody (Vector, Burlingame, CA, hTERT antagonizes p53-induced apoptosis independently of telomerase activityUSA), were used in HCT116 cells. Nuclei were visualized by Hoechst (Sigma, St Louis, MI, USA). Fluorescence images were collected and analysed using an Axioplan II (3D) microscope equipped with an AxioCam CCD camera (Carl Zeiss, Oberkochen, Germany).
